Eli Lilly has begun dosing COVID-19 patients in a phase 1 trial of its AbCellera-partnered antibody LY-CoV555. The initiation of the trial, which happened ahead of schedule, marks the start of a new phase of the response to SARS-CoV-2 in which study subjects will receive drugs designed specifically for the virus. Source: Fierce Biotech 1/6/2020